A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the ...

NXP800, a GCN2 kinase activator, has been on shaky ground since a data drop in November revealed a lack of efficacy. Seeking to improve outcomes, Nuvectis turned its attention to a new cohort of ...

Last week, Australian life sciences venture capital firm Brandon Capital closed its largest fund yet, raising A$439 million ...

AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. | AbbVie has reportedly added Gilgamesh ...

Maryland-based biotech NextCure is looking for partners to advance a candidate for the currently incurable rare disease ...

Medical AI company Cardiosense has claimed FDA clearance for its CardioTag device, a wearable sensor that provides a ...

Barcelona-based InBrain Neuroelectronics shared interim findings from a first-in-human clinical study of its graphene-based ...

The FDA has missed the date for Coya Therapeutics’ investigational new drug (IND) application, citing a lack of resources and ...

Siemens Healthineers' medtech peer Philips also cut its estimated tariff impact for the year following the U.S.-E.U. trade deal.

The bad news keeps on creeping toward Vyne Therapeutics’ BET inhibitor platform. | Weeks after the biotech gave up on a ...